ACADIA Pharmaceuticals (NASDAQ: ACAD) CFO trades 20,141 shares via plan
Rhea-AI Filing Summary
ACADIA Pharmaceuticals’ EVP and CFO Mark C. Schneyer exercised stock options covering 20,141 shares of common stock at an exercise price of $17.84 per share on August 5–6, 2026.
He then sold 20,141 shares in market transactions at prices around $29 per share under a Rule 10b5-1 trading plan adopted on May 19, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 20,141 shares ($228K approx. pre-tax spread)
Exercise and Sale
7 txns
Insider
Schneyer Mark C.
Role
EVP, CHIEF FINANCIAL OFFICER
Sold
20,141 shs ($587K)
Approx. gross sale proceeds
$587K
Approx. exercise cost
$359K
Approx. pre-tax spread
$228K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F4 | 14,292 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,292 | $17.84 | $255K |
| Sale | Common Stock F2 | 5,000 | $29.00 | $145K |
| Sale | Common Stock F2 | 9,292 | $29.3375 | $273K |
| Exercise | Stock Option (Right to Buy) F4 | 5,849 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 5,849 | $17.84 | $104K |
| Sale | Common Stock F2, F3 | 5,849 | $29.0029 | $170K |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,423 shares (Direct);
Common Stock — 67,828 shares (Direct)
Footnotes (4)
- F1. Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.
- F2. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4. 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
Key Figures
Options exercised: 20,141 shares
Shares sold: 20,141 shares
Exercise price: $17.84 per share
+4 more
7 metrics
Options exercised
20,141 shares
Stock options for common stock exercised on August 5–6, 2026 at $17.84 per share
Shares sold
20,141 shares
Common stock sold in market transactions on August 5–6, 2026 under a Rule 10b5-1 plan
Exercise price
$17.84 per share
Exercise price of stock options converted into ACADIA common stock
Sale price August 5
$29.0029 per share
Weighted average sale price for 5,849 shares on August 5, 2026; trades from $29.00–$29.02
Sale price August 6 (block 1)
$29.00 per share
Sale price for 5,000 shares of common stock on August 6, 2026
Sale price August 6 (block 2)
$29.3375 per share
Sale price for 9,292 shares of common stock on August 6, 2026
ESPP shares
1,683 shares
Shares acquired on May 15, 2026 under an employee stock purchase plan, per footnote
Key Terms
Rule 10b5-1 Plan, weighted average price, employee stock purchase plan, vest and become exercisable
4 terms
Rule 10b5-1 Plan regulatory
"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
employee stock purchase plan financial
"shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
vest and become exercisable financial
"25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did ACAD (ACADIA Pharmaceuticals) CFO Mark Schneyer report?
Mark C. Schneyer reported exercising stock options for 20,141 shares of ACADIA common stock at $17.84 per share, then selling 20,141 shares in market transactions on August 5–6, 2026 under a Rule 10b5-1 trading plan.
Were the ACAD CFO’s stock sales executed under a Rule 10b5-1 plan?
Yes. A footnote states the reported sale transactions occurred pursuant to a Rule 10b5-1 Plan adopted by Mark C. Schneyer on May 19, 2025, and the filing’s Rule 10b5-1 checkbox is affirmed for these transactions.
What was the exercise price of the ACADIA CFO’s stock options?
The exercised stock options had an exercise price of $17.84 per share. These options, covering a total of 20,141 shares of ACADIA common stock, were exercised on August 5–6, 2026 before the corresponding share sales.
How do the ACAD CFO’s option vesting terms relate to these exercises?
A footnote explains that 25% of the option shares vested on March 25, 2025, with the remaining shares vesting in 36 equal monthly installments thereafter, providing the exercisable stock options used in these August 2026 transactions.